euro adhoc: Marseille-Kliniken AG
Quarterly or Semiannual Financial
Statements
- 5 % increase in sales to EUR 150.3 million in the
first three quarters
- Overall earnings of EUR 6.2 million slowed down due to
macro-economic impacts in Rehabilitation
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
In the first three quarters of the fiscal year 2003/04, the Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) was able to further increase sales by 5.0% to EUR 150.3 million (previous year EUR 143.2 million). The earnings pursuant to DVFA/SG (IFRS) amounted to EUR 6.2 million compared with EUR 6.3 million in the previous year. The earnings per share came to EUR 0.51 following EUR 0.52 in the same period one year ago. Thus, for the most part the once again positive earnings trend in the Nursing division was able to offset the macro-economically and the seasonally impacted result in the Rehabilitation division in the 3rd quarter.
The occupancy rate in the entire Group amounted to 89.8% for the reference period compared with 92.3% one year ago. Besides the still low occupancy rate in the Rehabilitation division, the main reasons are four start-up facilities and four acquired facilities in the Nursing division in the previous fiscal year.
In its core segment Nursing, in which Marseille-Kliniken provides three quarters of the Groups total bed capacity, sales and earnings continued to improve considerably. With sales of EUR 108.3 million in this segment during the period under review, Marseille-Kliniken realized a rise in sales of EUR 11 million with respect to the EUR 97.3 million sales generated in the same period one year ago. The earnings pursuant to DVFA/SG (IFRS) were improved to EUR 8.6 million, up EUR 0.8 million from EUR 7.8 million.
In the Rehabilitation division a trend reversal with respect to the occupancy rate could not yet be experienced in the 3rd quarter of the current fiscal year. In particular in the psychosomatic unit, which accounts for 40% of the total capacities in the Rehabilitation segment, the cyclically-related decline in the occupancy rate in the 3rd quarter was disproportionately high. Accordingly, sales remained EUR 3.9 million below previous years level of EUR 45.9 million and amounted to EUR 42.0 million in the first nine months of the fiscal year 2003/04. Compared with the previous year, the earnings pursuant to DVFA/SG (IFRS) weakened by EUR -0.9 million to EUR -2.4 million (previous year EUR -1.5 million).
Due to seasonal effects and additional cost-reduction measures, we expect improved results in the Rehabilitation division in the 4th quarter and all in all reaffirm our forecast for the full-year to achieve a 7% rise in sales and a disproportionate increase in earnings.
end of announcement euro adhoc 07.05.2004
Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
Tel.: 030 / 246 32-400
Fax: 030 / 246 32-401
Christian Hillermann
Managing Director Haubrok IR
c.hillermann@haubrok.de
+49(0)211-30126-0
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share, Prime Standard
Börsen: Hamburger Wertpapierbörse / official dealing
Frankfurter Wertpapierbörse / official dealing
Berliner Wertpapierbörse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Börse Düsseldorf / free trade
Baden-Württembergische Wertpapierbörse / free trade